PDCD1 and cancer: Inhibitors of PD‐1 and PD‐L1 disrupt PD‐1/PD‐L1 axis, thereby reversing T‐cell suppression and enhancing endogenous antitumor immunity to unleash long‐term antitumor responses for patients with a wide range of cancers (Paterson et al., 2011).